TGF-beta antisense oligonucleotides modulate expression of matrix metalloproteinases in isolated fibroblasts from radiated skin

In Vivo

Volumn 22, Issue 1, 2008, Pages 1-8

  Riedel, Katrin ^a   Kremer, T ^a   Ryssel, H ^a   Riedel, F ^b   Goessler, U R ^b   Koellensperger, E ^a   Germann, G ^a   Sauerbier, M ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Fibroblasts; MMP; Radiation wound; TGF beta

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; COLLAGENASE 3; GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ANTISENSE THERAPY; ARTICLE; CELL ISOLATION; CHRONIC WOUND; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REGULATION; ENZYME RELEASE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MICROARRAY ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RADIATION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; WOUND HEALING;

EID: 40749102112     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Jung H, Beck-Bornholdt HP, Svoboda V, Alberti W and Herrmann T: Quantification of late complications after radiation therapy. Radiother Oncol 61: 233-246, 2001.
2. Harper JL, Franklin LE, Jenrette JM and Aguero EG: Skin toxicity during breast irradiation: pathophysiology and management. South Med J 97: 989-993, 2004.
3. Canney PA and Dean S: Transforming growth factor beta: a promotor of late connective tissue injury following radiotherapy? Br J Radiol 63: 620-623, 1990.
4. Archambeau JO, Pezner R and Wasserman T: Pathophysiology of irradiated skin and breast. Int J Radiat Oncol Biol Phys 31: 1171-1185, 1995.
5. Wall SJ, Bevan D, Thomas DW, Harding KG, Edwards DR and Murphy G: Differential expression of matrix metalloproteinases during impaired wound healing of the diabetic mouse. J Invest Dermatol 119: 91-98, 2002.
6. Denham JW and Hauer-Jensen M: The radiotherapeutic injury - a complex 'wound'. Radiother Oncol 63: 129-145, 2002.
7. Riedel F, Philipp K, Sadick H, Goessler U, Hormann K and Verse T: Immunohistochemical analysis of radiation-induced non-healing dermal wounds of the head and neck. In Vivo 19: 343-350, 2005.
8. Ravanti L and Kahari VM: Matrix metalloproteinases in wound repair. Int J Mol Med 6: 391-407, 2000.
9. Herskind C, Bamberg M and Rodemann HP: The role of cytokines in the development of normal-tissue reactions after radiotherapy. Strahlenther Onkol 174(Suppl 3): 12-15, 1998.
10. Cordeiro MF, Mead A, Ali RR, Alexander RA, Murray S, Chen C, York-Defalco C, Dean NM, Schultz GS and Khaw PT: Novel antisense oligonncleotides targeting TGF-beta inhibit in vivo scarring and improve surgical outcome. Gene Ther 10: 59-71, 2003,
11. Roberts AB and Sporn MB: Transforming growth factor-β In: The Molecular and Cellular Biology of Wound Repair, 2nd Ed., Clark RAF (ed.). Plenum Press New York, pp. 275-308, 1996.
12. Edwards DR, Murphy G, Reynolds JJ, Whitham SE, Docherty JP, Angel P and Heath JK: Transforming growth factor β modulates the expression of collagenase and metalloproteinase inhibitor. EMBO J 6: 1899-1904, 1987.
13. Parks WC: The production, role, and regulation of matrix metalloproteinases in the healing epidermis. Wounds 7: 23A-37A, 1995.
14. Han YP, Tuan TL, Hughes M, Wu H and Garner WL: Transforming growth factor-beta- and tumor necrosis factor-alpha-mediated induction and proteolytic activation of MMP-9 in human skin. J Biol Chem 276: 22341-22350, 2001.
15. Makela M, Larjava H, Pirila E, Maisi P, Salo T, Sorsa T and Uitto VJ: Matrix metalloproteinase 2 (gelatinase A) is related to migration of keratinocytes. Exp Cell Res 251: 67-78, 1999.
16. Huang JS, Wang YH, Ling TY, Chuang SS, Johnson FE and Huang SS: Synthetic TGF-beta antagonist accelerates wound healing and reduces scarring. FASEB J 16: 1269-1270, 2002.
17. Philipp K, Riedel F, Germann G, Hormann K and Sauerbier M: TGF-beta antisense oligonucleotides reduce mRNA expression of matrix metalloproteinases in cultured wound-healing-related cells. Int J Mol Med 15: 299-303, 2005.
18. Philipp K, Riedel F, Sauerbier M, Hormann K and Germann G: Targeting TGF-beta in human keratinocytes and its potential role in wound healing. Int J Mol Med 14: 589-593, 2004,
19. Riedel K, Riedel F, Goessler UR, Germann G and Sauerbier M: TGF-beta antisense therapy increases angiogenic potential in human keratinocytes in vitro. Arch Med Res 38: 45-51, 2007.
20. Defacque H, Piquemal D, Basset A, Marti J and Commes T: Transforming growth factor-beta1 is an autocrine fine mediator of U937 cell growth arrest and differentiation induced by vitamin D3 and retinoids. J Cell Physiol 178: 109-119, 1999.
21. Miller SH and Rudolph R: Healing in the irradiated wound. Clin Plast Surg 17: 503-508, 1990.
22. Yager DR and Nwomeh BC: The proteolytic environment of chronic wounds. Wound Rep Regen 7: 433-441, 1999,
23. Falanga V: Chronic wounds: pathophysiologic and experimental consideration. J Invest Dermatol 100: 721-725, 1993.
24. Bennett NT and Schultz GS: Growth factors and wound healing: biochemical properties of growth factors and their receptors. Am J Surg 165: 728-737, 1993.
25. Agren MS: Matrix metalloproteinases (MMPs) are required for re-epithelialization of cutaneous wounds. Arch Dermatol Res 291: 583-590, 1999.
26. Pattison PS: The importance of reassessment to chronic wound care. Ostom Wound Manage 47: 24-25, 2001.
27. Kähäri VM and Saarialho-Kere U: Matrix metalloproteinases in skin. Exp Dermatol 6: 199-213, 1997.
28. Soo C, Shaw WW, Zhang X, Longaker MT, Howard EW and Ting K: Differential expression of matrix metalloproteinases and their tissue-derived inhibitors in cutaneous wound repair. Plast Reconstr Surg 105: 638-647, 2000.
29. Baker EA and Leaper DJ: Proteinases, their inhibitors, and cytokine profiles in acute wound fluid. Wound Repair Regen 8: 392-398, 2000.
30. Weckroth M, Vaheri A, Lauharanta J, Sorsa T and Konttinen YT: Matrix metalloproteinases, gelatinase and collagenase, in chronic leg ulcers. J Invest Dermatol 106: 1119-1124, 1996.
31. Williams RL and Armstrong DG: Wound healing. New modalities for a new millennium. Clin Podiatr Med Surg 15: 117-128, 1998.
32. Riedel K, Riedel F, Goessler UR, Holle G, Germann G and Sauerbier M: Current status of genetic modulation of growth factors in wound repair. Int J Mol Med 17: 183-193, 2006.
33. Hernandez A and Evers BM: Functional genomics: clinical effect and the evolving role of the surgeon. Arch Surg 134: 1209-1215, 1999.
34. Khavari PA, Rollman O and Vahlquist A: Cutaneous gene transfer for skin and systemic diseases. J Intern Med 252: 1-10, 2002.
35. Saito S, Trovato MJ, You R, Lal BK, Fasehun F, Padberg FT Jr, Hobson RW II, Duran WN and Pappas PJ: Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 34: 930-938, 2001.
36. Shah M, Foreman DM and Ferguson MWJ: Neutralisation of TGF-β1 and TGF-β2 or exogenous addition of TGF-β3 to cutaneous wounds reduces scarring. J Cell Sci 108: 983-1002, 1995.
37. Pirollo KF, Rait A, Sleer LS and Chang EH: Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 99: 55-77, 2003.
38. Wacheck V: Oligonucleotide therapeutics - an emerging novel class of compounds. Wien Med Wochenschr 156: 481-487, 2006.
39. Wraight CJ and White PJ: Antisense oligonucleotides in cutaneous therapy. Pharmacol Ther 90: 89-104, 2001.
40. Schiavone N, Donnini M, Nicolin A and Capaccioli S: Antisense oligonucleotide drug design. Curr Pharm Des 10: 769-784, 2004.
41. Mirabelli CK, Bennett CF, Anderson K and Crooke ST: In vitro and in vivo pharmacologic activities of antisense oligonucleotides. Anticancer Drug Des 6: 647-661, 1991.
42. Choi BM, Kwak HJ, Jun CD, Park SD, Kim KY, Kim HR and Chung HT: Control of scarring in adult wounds using antisense transforming growth factor-beta 1 oligodeoxynucleotides. Immunol Cell Biol 74: 144-150, 1996.
43. Field AK and Goodchild J: Antisense oligonucleotides: Rational drug design for genetic pharmacology. Exp Opin Invest Drugs 4: 799-821, 1995.
44. Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D and Eckhardt SG: Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer. J Clin Oncol 17: 3586-3595, 1999.